CPRX Profile
Catalyst Pharmaceuticals, Inc., a leading biopharmaceutical firm, specializes in the development and commercialization of therapies targeting rare and debilitating neuromuscular and neurological conditions across the United States. The company's flagship product, Firdapse, comprises amifampridine phosphate tablets specifically formulated for individuals suffering from Lambert-Eaton myasthenic syndrome (LEMS). Additionally, Catalyst Pharmaceuticals offers Ruzurgi, tailored to pediatric patients afflicted with LEMS, further solidifying its commitment to addressing unmet medical needs in this niche patient population.
Beyond its current portfolio, Catalyst Pharmaceuticals is actively expanding therapeutic applications for Firdapse. Ongoing development efforts include exploring treatments for MuSK antibody positive myasthenia gravis, spinal muscular atrophy type 3, and hereditary neuropathy with liability to pressure palsies, reflecting the company's dedication to advancing treatment options for diverse neurological disorders. Catalyst Pharmaceuticals has forged strategic alliances, including license agreements with BioMarin Pharmaceutical Inc., and a collaboration with Endo Ventures Limited aimed at the development and commercialization of generic Sabril tablets.
Founded in 2002 and originally known as Catalyst Pharmaceutical Partners, Inc., the company rebranded as Catalyst Pharmaceuticals, Inc. in May 2015. Headquartered in Coral Gables, Florida, Catalyst Pharmaceuticals continues to drive innovation in the biopharmaceutical sector through rigorous research and development initiatives. The company's location in Florida strategically positions it within a vibrant biotechnological hub, fostering collaborations and partnerships that support its mission to improve the lives of patients with rare neurological disorders.
With a steadfast commitment to scientific excellence and patient-centric innovation, Catalyst Pharmaceuticals remains at the forefront of advancing therapies that address the complexities of rare neuromuscular and neurological diseases. Through its comprehensive approach to drug development and strategic partnerships, the company is poised to make significant strides in enhancing treatment outcomes and quality of life for patients nationwide.
|
